Overexpression of interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 67-75

  Suchi, Kentaro ^a   Fujiwara, Hitoshi ^a   Okamura, Shinichi ^a   Okamura, Hiroko ^a   Umehara, Seiji ^a   Todo, Momoko ^a   Furutani, Akinobu ^a   Yoneda, Masayuki ^a   Shiozaki, Atsushi ^a   Kubota, Takeshi ^a   Ichikawa, Daisuke ^a   Okamoto, Kazuma ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Chemosensitivity; Cisplatin; Esophageal cancer; IL 6

Indexed keywords

CISPLATIN; INTERLEUKIN 6; PLASMID VECTOR; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 79851470620     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Isono K, Sato H and Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48: 411-420, 1991.
2. Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T and Okudaira Y: Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet 157: 537-540, 1983. (Pubitemid 14201132)
3. Tachimori Y and Kato H: Diagnosis and surgery of esophageal cancer. Crit Rev Oncol Hematol 28: 57-71, 1998.
4. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L and Emami B: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncol 15: 277-284, 1997.
5. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr., Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV and Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281: 1623-1627, 1999. (Pubitemid 29211772)
6. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007. (Pubitemid 46291702)
8. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
9. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
10. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
11. Hirano T: Interleukin-6 and its receptor: ten years later. Int Rev Immunol 16: 249-284, 1998.
12. Akira S and Kishimoto T: The evidence for interleukin-6 as an autocrine growth factor in malignancy. Semin Cancer Biol 3: 17-26, 1992.
13. Aoyagi T, Takishima K, Hayakawa M and Nakamura H: Gene expression of TGF-alpha, EGF and IL-6 in cultured renal tubular cells and renal cell carcinoma. Int J Urol 3: 392-396, 1996. (Pubitemid 26332125)
14. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travail S and D'Alessandro N: Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85: 134-144, 1999. (Pubitemid 29031367)
15. Kinoshita T, Ito H and Miki C: Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85: 2526-31, 1999. (Pubitemid 29272736)
16. Schwarze MM and Hawley RG: Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 55: 2262-265, 1995.
17. Chen RH, Chang MC, Su YH, Tsai YT and Kuo ML: Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 274: 23013-23019, 1999.
18. Jee SH, Shen SC, Chiu HC, Tsai WL and Kuo ML: Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 20: 198-208, 2001.
19. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ and Li LZ: Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 295: 110-123, 2010.
20. Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL and Hsieh CY: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20: 5799-5809, 2001.
21. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y and Yoshida O: Sensitization of human renal cell carcinoma cells to cis- diamminedichloroplatinum(11) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55: 590-596, 1995.
22. Wang LS, Chow KC and Wu CW: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by TV-sodium butyrate. Br J Cancer 80: 1617-1622, 1999.
23. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T and Suzuki T: Relationship between serum levels of interleukin-6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56: 2776-2780, 1996. (Pubitemid 26175737)
24. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA and Fearon KC: Elevated tumour interleukin-1 beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95: 1568-1575, 2006.
25. Leu CM, Wong FH, Chang C, Huang SF and Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22: 7809-7818, 2003. (Pubitemid 37485540)
26. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T and Suzuki T: The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 16: 1001-1006, 1996.
27. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T and Otsuji E: Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2010 Oct 28.
28. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
29. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P and Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808, 1992.
30. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB and Ajani JA: Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24: 748-754, 2006. (Pubitemid 46622041)
31. Maeda M, Watanabe N, Okamoto T, Tsuji N and Niitsu Y: Endogenous tumor necrosis factor functions as a resistant factor against adriamycin. Int J Cancer 58: 376-379, 1994. (Pubitemid 24254647)